Biotechnology
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium
CHENGDU, China, Feb. 13, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held inSan Francisco, USA, from Feb. 13-15, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd （"Kelun-Biotech" will present efficacy and safety ...
2025-02-13 11:25
2497
Southern Star Research Applauded by Frost & Sullivan for Delivering Comprehensive Clinical Trial Solutions and Its Competitive Strategies
Southern Star sets itself apart in the CRO market through a unique combination of trust, operational advantages, deep industry expertise, and a strong commitment to local resources. SAN ANTONIO, Feb. 13, 2025 /PRNewswire/ -- Frost & Sullivan recently analyzed the biotechnology contract research ...
2025-02-13 10:30
2411
Sequential and AMILI Secure Prestigious $1.8M UK-Singapore Collaborative R&D Project to Advance Gut-Skin Microbiome Science
LONDON, Feb. 13, 2025 /PRNewswire/ -- Sequential Skin Ltd, a world leader in skin microbiome testing, and AMILI, a leading expert in gut microbiome science, are proud to announce that they have been awarded the prestigious UK-Singapore Collaborative R&D Grant. The$1.8 million project, supported b...
2025-02-13 06:00
3038
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
SINGAPORE, Feb. 12, 2025 /PRNewswire/ -- On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international multicenter Phase 2 clinical trial. This ...
2025-02-12 09:00
5142
Sustainable Leather Technology Advances With Collaboration Between Meatable and Pelagen
LEIDEN, Netherlands, Feb. 11, 2025 /PRNewswire/ -- Meatable, a leader in cultivated meat technology, has started a collaboration effort withPelagen, a pioneering company focused on developing animal-free leather. This collaboration enables Pelagen to explore the use of the award-winning opti-ox™ ...
2025-02-11 20:04
2918
Infinitus Secures Approval for National-Level Joint Laboratory Project, Ushering in a New Chapter of China-Europe Scientific Research Collaboration
GUANGZHOU, China, Feb. 10, 2025 /PRNewswire/ – In a significant announcement at the recent Infinitus Global Annual Meeting, Infinitus (China) Company Ltd. secured approval for its Sino-British Joint Laboratory on Health and Aging project. This initiative is part of the intergovernmental internati...
2025-02-11 15:27
4367
Bio X Cell Expands Global Reach with New Distribution Center in Beijing, China
LEBANON, N.H., Feb. 11, 2025 /PRNewswire/ -- Bio X Cell, the world's leading provider of functional antibodies for translational research, is strengthening its global distribution network with the opening of a new distribution center in Beijing, China, in March 2025. This expansion marks the lates...
2025-02-11 15:00
2428
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along wit...
2025-02-06 19:40
4382
Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer
SUZHOU, China, Feb. 6, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (...
2025-02-06 14:05
4123
Medidata Advances New Frontiers for Life Sciences Through Patient-Centric Experiences, AI-Powered Innovations, and New Patient Engaging Alliances
In the era of the generative economy, Medidata is transforming how industries
are empowering patients with new cure and care experiences and lifelong
engagement
SINGAPORE, Feb. 6, 2025 /PRNewswire/ -- Medidata
2025-02-06 13:00
4979
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
* Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC * Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC * Serplulimab has now been approved in China, Europe, and sev...
2025-02-05 22:05
4458
AI & Genomics Advances Bring New Hope to Lung Cancer Burden in Asia
SINGAPORE, Feb. 5, 2025 /PRNewswire/ -- Asia is the region most impacted by lung cancer, accounting for 63.1% of newly diagnosed lung cancers and 62.9% of lung cancer deaths worldwide(1). Many countries have applied low-dose CT scans to screen for this deadly cancer to improve early detection an...
2025-02-05 14:00
6640
Aussie sleeptech firm unveils breakthrough test
MELBOURNE, Australia, Feb. 5, 2025 /PRNewswire/ -- Australian medical technology company Optalert has revealed a breakthrough test for sleep issues, expanding access to sleep health technologies for millions of Australians. The simple test is conducted within 10 minutes on a smartphone, making it...
2025-02-05 13:36
2891
NABR Applauds CITES Standing Committee's Decision Not to Enact Trade Suspension on Cambodia's Long-Tailed Macaques
WASHINGTON, Feb. 5, 2025 /PRNewswire/ -- The National Association for Biomedical Research (NABR) commends the CITES Standing Committee's decision not to enact a trade suspension on long-tailed macaques (Macaca fascicularis) from Cambodia. This decision underscores the international community's st...
2025-02-05 06:48
3952
Bayer Foundation Women Entrepreneurs Award: Applications Open for Innovators in Health and Food Security
LEVERKUSEN, Germany, Feb. 4, 2025 /PRNewswire/ -- Bayer Foundation, in
partnership withImpact Hub Network, has opened applications
2025-02-04 16:01
4974
Kinectrics and Isotopia Enter Agreement for Supply of Gadolinium-160 (Gd-160) to Support Production of Terbium-161 (Tb-161) for Advanced Radiotherapeutics
TORONTO, Jan. 30, 2025 /PRNewswire/ -- Kinectrics and Isotopia have announced a groundbreaking agreement under which Kinectrics will provide Isotopia with a reliable supply of Gadolinium-160 (Gd-160). This critical isotope will enable Isotopia's production of Terbium-161 (Tb-161), a medical isoto...
2025-01-30 12:00
4069
Advanced Aesthetic Technologies, Inc. is pleased to announce the approval of Algeness® VL agarose facial injection filler for marketing in China
AAT announces additional significant updates RADNOR, Pa., Jan. 29, 2025 /PRNewswire/ -- Advanced Aesthetic Technologies, Inc. ("AAT") announced today that their partner inChina has obtained approval to market their unique dermal filler Algeness® VL agarose facial injection filler, a 2.5% agarose...
2025-01-29 14:00
4190
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities
The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers BOSTON, MA and ROLLE, Switzerland, Jan. 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-dr...
2025-01-28 22:07
3936
ThinkCyte expands product portfolio to drive innovation in drug discovery and disease research.
TOKYO, Jan. 28, 2025 /PRNewswire/ -- ThinkCyte, a biotechnology company pioneering novel artificial intelligence (AI)-based cell analysis and sorting instruments, announced today that it will begin the pre-commercial launch of its new cell analysis platform, VisionCyte™. The announcement coincide...
2025-01-28 00:00
4320
Seeking Investors: First-in-Class Immunotherapeutics for Cancer
ATLANTA, Jan. 27, 2025 /PRNewswire/ -- Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug is mutation-agnostic, and the company observes no toxicity-limiting dosages. In ...
2025-01-27 19:58
4009
Week's Top Stories
Most Reposted
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 298 media titles]
2026-06-04 23:55
DayOne Appoints Nicolas Aguzin to Board of Directors, Strengthening Global Governance and Capital Markets Expertise
[Picked up by 281 media titles]
2026-05-29 15:50Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Creality 3D Successfully Listed in Hong Kong
[Picked up by 271 media titles]
2026-05-29 11:21
PHOTO & IMAGE SHANGHAI 2026 to Showcase AI Imaging, Content-Creation Technologies and Emerging Visual Trends This July
[Picked up by 269 media titles]
2026-05-29 17:36
Most Read
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
8232
AMTD's Successful Completion of Acquisition of The Ritz-Carlton, Perth, Valued at A$280 Million
2026-05-29 21:50
7623
Creality 3D Successfully Listed in Hong Kong
2026-05-29 11:21
7180
Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering
2026-05-29 22:00
6740